Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
Soo Heon KwakKyung Ah HanKyung-Soo KimJae Myung YuEunSook KimJong Chul WonJun Goo KangChoon Hee ChungSeungjoon OhSung Hee ChoiKyu Chang WonSin Gon KimSeung Ah ChoBo Young ChoKyong Soo ParkPublished in: Diabetes, obesity & metabolism (2023)
Monotherapy with enavogliflozin 0.3 mg improved glycaemic control in people with T2DM. Enavogliflozin therapy also exerted beneficial effects on body weight, blood pressure and lipid profile.